Posted on October 11, 2018
Archive : October 2018
Category : News

Clinical Research has contributed to the success of the influenza vaccine

Over the years Clinical Researchers have been at the forefront of helping to trial and test medications that contribute to improving our everyday lives.   A very good example of this is the Influenza vaccine.

Dr Essam Abdulhakim, Chief Medical Officer for MeDiNova Research explains:

“We are now at the time of year in the autumn where GP surgeries and pharmacists are encouraging people to get their vaccines against influenza.

“Influenza, commonly known as “the flu”, is a contagious respiratory infection caused by several flu viruses that infect the nose, throat and lungs. Flu is a seasonal virus which usually occurs in the autumn and winter months and affects people in many ways, often causing fever, coughing, congestions, headache, aches and fatigue.  It usually lasts for about a week or two.  However, for some people it can cause serious complications for example pneumonia, which can result in them being hospitalised.

“Seasonal epidemics on a global scale usually affect about three* to five* million cases yearly of severe illness (*World Health Organisation figures),and this increases dramatically in some pandemic years.

“Pandemic influenza is when a new flu virus strain occurs that can spread easily from person-to-person and the virus is one for which most people have no immunity.  While the most well-known pandemic was in 1918, recent pandemics have been caused by a variety of strains and even evolved from animals, such as swine flu.

“New flu vaccines are developed and produced each year, as flu strains often change and people who are susceptible are advised to have the flu vaccines every year to help prevent them being affected.

“The Flu vaccine is the best protection to mitigate the effect of flu and help prevent people from getting flu. Although it is not guaranteed to stop all flu viruses the vaccination does mean that it is more likely that the effect will be milder and that the virus won’t last as long.

“It is testimony to the work of clinical researchers on behalf of the pharmaceutical industry that we have a successful programme of yearly flu vaccines, helping to create a solution to reduce the effects of flu and lessen its impact across the globe.”